文献速递类风湿关节炎

瑞士类风湿关节炎队列中TNF抑制剂、其他机制生物制剂与托法替布的疗效比较

Comparative effectiveness of antitumour necrosis factor agents, biologics with an alternative mode of action and tofacitinib in an observational cohort of patients with rheumatoid arthritis in Switzerland.
PubMed 文献 · RMD Open · 2020-01-01

该研究嵌套于瑞士RA注册队列,纳入4023个疗程(TNFi 1862、bDMARD-OMA 1355、托法替布806),比较药物留存与临床有效性。托法替布留存与bDMARD-OMA相当,优于TNFi;TNFi需联用csDMARDs才能达到最佳有效性,而bDMARD-OMA或托法替布则不需要。

要点

  • 托法替布药物留存与bDMARD-OMA相当,高于TNFi。
  • TNFi不联用csDMARDs时留存下降,bDMARD-OMA或托法替布无此差异。
  • TNFi更常作为首个b/tsDMARDs使用,患者年龄更轻、病程更短。

核心结论

  • 托法替布药物留存与bDMARD-OMA相当,略高于TNFi。
  • TNFi达到最佳有效性需要联用csDMARDs,而bDMARD-OMA或托法替布不需要。

研究设计与样本

  • 观察性队列研究,嵌套于瑞士RA注册队列。
  • 纳入成人RA患者起始的TNFi、bDMARD-OMA(阿巴西普或抗IL-6药物)或托法替布治疗。
  • 共纳入2600例患者的4023个治疗疗程:TNFi 1862、bDMARD-OMA 1355、托法替布806。

主要发现

  • 总体药物留存TNFi显著低于托法替布[HR 1.29(95%CI 1.14至1.47)]。
  • bDMARD-OMA与托法替布的药物留存相似[HR 1.09(95%CI 0.96至1.24)]。
  • TNFi不联用csDMARDs时留存下降[HR 1.27(95%CI 1.08至1.49)],而bDMARD-OMA或托法替布联用与否无差异。

关键数值与推荐

  • 主要结局为总体药物留存。
  • 次要结局为临床有效性,并分析联用csDMARDs是否修饰有效性,调整潜在混杂因素。

临床怎么用

  • 选择TNFi时应考虑联用csDMARDs以优化有效性。
  • 托法替布或bDMARD-OMA可作为TNFi之外的替代选择,单药治疗时留存不受联用csDMARDs影响。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Multiple biologic and targeted synthetic disease-modifying rheumatic drugs (b/tsDMARDs) are approved for the management of rheumatoid arthritis (RA), including TNF inhibitors (TNFi), bDMARDs with other modes of action (bDMARD-OMA) and Janus kinase inhibitors (JAKi). Combination of b/tsDMARDs with conventional synthetic DMARDs (csDMARDs) is recommended, yet monotherapy is common in practice. OBJECTIVE: To compare drug maintenance and clinical effectiveness of three alternative treatment options for RA management. METHODS: This observational cohort study was nested within the Swiss RA Registry. TNFi, bDMARD-OMA (abatacept or anti-IL6 agents) or the JAKi tofacitinib (Tofa) initiated in adult RA patients were included. The primary outcome was overall drug retention. We further analysed secondary effectiveness outcomes and whether concomitant csDMARDs modified effectiveness, adjusting for potential confounding factors. RESULTS: 4023 treatment courses of 2600 patients were included, 1862 on TNFi, 1355 on bDMARD-OMA and 806 on Tofa. TNFi was more frequently used as a first b/tsDMARDs, at a younger age and with shorter disease duration. Overall drug maintenance was significantly lower with TNFi compared with Tofa [HR 1.29 (95% CI 1.14 to 1.47)], but similar between bDMARD-OMA and Tofa [HR 1.09 (95% CI 0.96 to 1.24)]. TNFi maintenance was decreased when prescribed without concomitant csDMARDs [HR: 1.27 (95% CI 1.08 to 1.49)], while no difference was observed for bDMARD-OMA or Tofa maintenance with respect to concomitant csDMARDs. CONCLUSION: Tofa drug maintenance was comparable with bDMARDs-OMA and somewhat higher than TNFi. Concomitant csDMARDs appear to be required for optimal effectiveness of TNFi, but not for bDMARD-OMA or Tofa.

来源:RMD Open,查看原文。版权归原作者所有。

引用

  1. Finckh A, Tellenbach C, Herzog L, et al. Comparative effectiveness of antitumour necrosis factor agents, biologics with an alternative mode of action and tofacitinib in an observational cohort of patients with rheumatoid arthritis in Switzerland. RMD Open. 2020. PMID: 32385143. doi:10.1136/rmdopen-2020-001174

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。